Is Harrow Health Stock a Good Investment?
Harrow Health Investment Advice | HROW |
- Examine Harrow Health's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Harrow Health's leadership team and their track record. Good management can help Harrow Health navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Harrow Health's business and its evolving consumer preferences.
- Compare Harrow Health's performance and market position to its competitors. Analyze how Harrow Health is positioned in terms of product offerings, innovation, and market share.
- Check if Harrow Health pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Harrow Health's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Harrow Health stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Harrow Health is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Harrow Health Stock
Researching Harrow Health's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.95. Harrow Health had not issued any dividends in recent years. The entity had 1:5 split on the 8th of February 2013.
To determine if Harrow Health is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Harrow Health's research are outlined below:
| Harrow Health generated a negative expected return over the last 90 days | |
| Harrow Health has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 130.19 M. Net Loss for the year was (24.41 M) with profit before overhead, payroll, taxes, and interest of 122.73 M. | |
| About 59.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Acquisition by Shojaei Amir of 30000 shares of Harrow Health at 35.96 subject to Rule 16b-3 |
Harrow Health Quarterly Gross Profit |
|
Harrow Health uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Harrow Health. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Harrow Health's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Harrow Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Harrow Health's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-08-14 | 2019-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2024-08-07 | 2024-06-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2020-03-13 | 2019-12-31 | 0.06 | 0.1 | 0.04 | 66 | ||
2015-03-12 | 2014-12-31 | -0.26 | -0.3 | -0.04 | 15 | ||
2021-05-11 | 2021-03-31 | -0.04 | 0.01 | 0.05 | 125 | ||
2019-11-13 | 2019-09-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2014-11-12 | 2014-09-30 | -0.25 | -0.3 | -0.05 | 20 | ||
2021-08-10 | 2021-06-30 | -0.03 | -0.09 | -0.06 | 200 |
Know Harrow Health's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Harrow Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Harrow Health backward and forwards among themselves. Harrow Health's institutional investor refers to the entity that pools money to purchase Harrow Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royce & Associates, Lp | 2024-09-30 | 360.3 K | Nuveen Asset Management, Llc | 2024-09-30 | 328.9 K | First Turn Management Llc | 2024-09-30 | 326.6 K | Rice Hall James & Associates, Llc | 2024-12-31 | 310.5 K | Northern Trust Corp | 2024-09-30 | 296.8 K | Renaissance Technologies Corp | 2024-09-30 | 293.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 255.2 K | Voloridge Investment Management, Llc | 2024-09-30 | 215.7 K | Gilder Gagnon Howe & Co Llc | 2024-09-30 | 209.5 K | Opaleye Management Inc | 2024-09-30 | 4 M | Blackrock Inc | 2024-09-30 | 2.3 M |
Harrow Health's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.08 B.Market Cap |
|
Harrow Health's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.15) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.31) | (0.33) |
Determining Harrow Health's profitability involves analyzing its financial statements and using various financial metrics to determine if Harrow Health is a good buy. For example, gross profit margin measures Harrow Health's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Harrow Health's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Harrow Health's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Harrow Health. Check Harrow Health's Beneish M Score to see the likelihood of Harrow Health's management manipulating its earnings.
Evaluate Harrow Health's management efficiency
Harrow Health has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5023) %, meaning that it created substantial loss on money invested by shareholders. Harrow Health's management efficiency ratios could be used to measure how well Harrow Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 0 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (0.15). At this time, Harrow Health's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 168.4 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (2.3 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.48 | 2.13 | |
| Tangible Book Value Per Share | (3.24) | (3.08) | |
| Enterprise Value Over EBITDA | 44.59 | 46.82 | |
| Price Book Value Ratio | 5.94 | 11.43 | |
| Enterprise Value Multiple | 44.59 | 46.82 | |
| Price Fair Value | 5.94 | 11.43 | |
| Enterprise Value | 433.6 M | 455.2 M |
The management team at Harrow Health has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 0.688 |
Basic technical analysis of Harrow Stock
As of the 16th of February 2025, Harrow Health retains the Standard Deviation of 4.07, risk adjusted performance of (0.12), and Market Risk Adjusted Performance of (0.46). Harrow Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Harrow Health market risk adjusted performance and treynor ratio to decide if Harrow Health is priced fairly, providing market reflects its last-minute price of 30.42 per share. Given that Harrow Health has information ratio of (0.18), we strongly advise you to confirm Harrow Health's regular market performance to make sure the company can sustain itself at a future point.Harrow Health's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Harrow Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Harrow Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Harrow Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Harrow Health's Outstanding Corporate Bonds
Harrow Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Harrow Health uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Harrow bonds can be classified according to their maturity, which is the date when Harrow Health has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Harsco 575 percent Corp BondUS415864AM90 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Harrow Health's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Harrow Health's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.46) | |||
| Mean Deviation | 2.92 | |||
| Coefficient Of Variation | (550.94) | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.6 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.47) | |||
| Maximum Drawdown | 21.05 | |||
| Value At Risk | (5.48) | |||
| Potential Upside | 6.58 | |||
| Skewness | (0.64) | |||
| Kurtosis | 3.37 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.46) | |||
| Mean Deviation | 2.92 | |||
| Coefficient Of Variation | (550.94) | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.6 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.47) | |||
| Maximum Drawdown | 21.05 | |||
| Value At Risk | (5.48) | |||
| Potential Upside | 6.58 | |||
| Skewness | (0.64) | |||
| Kurtosis | 3.37 |
Consider Harrow Health's intraday indicators
Harrow Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Harrow Health stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Harrow Health Corporate Filings
F4 | 24th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 8th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 5th of December 2024 An amended filing to the original Schedule 13G | ViewVerify |
Harrow Stock media impact
Far too much social signal, news, headlines, and media speculation about Harrow Health that are available to investors today. That information is available publicly through Harrow media outlets and privately through word of mouth or via Harrow internal channels. However, regardless of the origin, that massive amount of Harrow data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Harrow Health news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Harrow Health relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Harrow Health's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Harrow Health alpha.
Harrow Health Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Harrow Health can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Harrow Health Maximum Pain Price Across April 17th 2025 Option Contracts
Harrow Health's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Harrow Health close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Harrow Health's options.
Harrow Health Corporate Management
| Robert DDS | Special Advisor | Profile | |
| Jamie Webb | Director Relations | Profile | |
| PharmD Shojaei | Chief Officer | Profile | |
| David Moufarrge | VP Technology | Profile | |
| RPh Mannebach | Head Pharmacovigilance | Profile | |
| Brett Burrell | Vice Compliance | Profile | |
| CFA CMA | CFO Sec | Profile |
Additional Tools for Harrow Stock Analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.